Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema
Sign Up to like & getrecommendations! Published in 2017 at "Graefe's Archive for Clinical and Experimental Ophthalmology"
DOI: 10.1007/s00417-017-3624-y
Abstract: PurposeTo evaluate the visual and anatomical outcomes following switching therapy from bevacizumab to aflibercept in patients with persistent diabetic macular edema (DME).MethodsPatients with DME and central macular thickness (CMT) >300 μm on spectral domain optical coherence… read more here.
Keywords: bevacizumab aflibercept; bevacizumab; diabetic macular; switching therapy ... See more keywords
Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double‐masked, placebo‐controlled feasibility study.
Sign Up to like & getrecommendations! Published in 2019 at "Acta Ophthalmologica"
DOI: 10.1111/aos.14282
Abstract: To determine the feasibility of a definitive study of intravitreal ranibizumab to promote the clearance of persistent diabetic vitreous haemorrhage and thereby avoid vitrectomy. read more here.
Keywords: diabetic vitreous; vitreous haemorrhage; study; feasibility ... See more keywords
Serum pro‐inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti‐VEGF: association with intravitreal injection treatment profiles in real‐world setting
Sign Up to like & getrecommendations! Published in 2019 at "Acta Ophthalmologica"
DOI: 10.1111/aos.14308
Abstract: To study the role of serum levels of pro‐inflammatory factors in the identification of persistent diabetic macular oedema (DME) cases with limited anatomic response to anti‐VEGF. Additionally, possible predictive associations between serum factors and intravitreal… read more here.
Keywords: limited anatomic; macular oedema; diabetic macular; inflammatory factors ... See more keywords
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Ophthalmology"
DOI: 10.1155/2018/4171628
Abstract: Purpose To compare the visual and anatomic outcomes in patients with persistent diabetic macular edema (DME) who switched from ranibizumab to aflibercept with those who continued with previous ranibizumab therapy. Methods In this retrospective comparative… read more here.
Keywords: aflibercept ranibizumab; ranibizumab; diabetic macular; group ... See more keywords
Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Ophthalmology"
DOI: 10.1177/1120672120901691
Abstract: Objective: To evaluate, in the setting of persistent diabetic macular edema, the impact that continuous fluocinolone acetonide delivery has on treatment burden, visual acuity, central retinal thickness, and intraocular pressure. Materials and methods: A single-center,… read more here.
Keywords: diabetic macular; fluocinolone acetonide; fluocinolone; persistent diabetic ... See more keywords
One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
Sign Up to like & getrecommendations! Published in 2021 at "Taiwan Journal of Ophthalmology"
DOI: 10.4103/tjo.tjo_85_20
Abstract: PURPOSE: The aim of this study is to evaluate the functional and anatomical effects of switching from bevacizumab to aflibercept in patients with persistent diabetic macular edema (DME) resistant to bevacizumab. MATERIALS AND METHODS: Patients… read more here.
Keywords: bevacizumab; macular; diabetic macular; resistant bevacizumab ... See more keywords